{"nctId":"NCT00113607","briefTitle":"An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer","startDateStruct":{"date":"2005-04"},"conditions":["Ovarian Cancer"],"count":672,"armGroups":[{"label":"DOXIL + trabectedin","type":"EXPERIMENTAL","interventionNames":["Drug: Trabectedin","Drug: DOXIL","Drug: Dexamethasone"]},{"label":"DOXIL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DOXIL"]}],"interventions":[{"name":"Trabectedin","otherNames":["Yondelis"]},{"name":"DOXIL","otherNames":["CAELYX"]},{"name":"Dexamethasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer\n* Prior treatment with only 1 platinum based chemotherapy regimen\n* Eastern Cooperative Oncology Group status of not more than 2\n* Progression more than 6 months after the start of initial chemotherapy treatment\n\nExclusion Criteria:\n\n* Treatment with more than 1 prior chemotherapy regimen\n* Progression within 6 months after starting initial chemotherapy\n* Prior exposure to anthracyclines\n* Unwilling or unable to have central venous catheter\n* Known clinically relevant central nervous system metastasis","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS): Independent Radiologist Review","description":"PFS is defined as the time between randomization and disease progression or death.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time between the randomization and death","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) - Independent Radiologist Review","description":"Percentage of participants who achieved complete response (CR) or partial response (PR) as best overall response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR)= greater than or equal to 30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response: Independent Radiologist Review","description":"Duration of response was defined only for participants who had complete response or partial response as best overall response. Duration of response was calculated from the date of first documentation of response (not the confirmation) to the date of disease progression or death due to progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Area Under Curve (AUC) of Trabectedin.","description":"Median simulated area under the curve (AUC) of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil, calculated using the trapezoidal rule method. Simulations were based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (Participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Maximum Plasma Concentration (Cmax) of Trabectedin.","description":"Median simulated maximum plasma concentration (Cmax) at 3 hour of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil. The assessment of Cmax was based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13394","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":133,"n":333},"commonTop":["Nausea","Neutropenia","Vomiting","Fatigue","Palmar-Plantar Erythrodysaesthesia Syndrome"]}}}